低albuminemia的严重程度对3天的负载剂量后的整体teicoplanin度的影响:一个追溯的观察性研究
Yuki Shimizu1, Kazuhiko Hanada2, Takeaki Watanabe1
1Department of Pharmacy, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan.
概括
较低的泰可普拉宁总度与更严重的低albuminemia见,但自由度可能不会受到影响. 对低albuminemia进行teicoplanin目标调整可以改善患者的治疗结果.
科学领域:
- 药理动力学 药理动力学
- 内部医学 内部医学
- 传染性疾病 传染性疾病
背景情况:
- 众所周知,低albuminemia可以降低整体teicoplanin (TEIC) 度.
- 低albuminemia严重程度对TEIC总度的影响需要进一步调查.
- 这项研究考察了低albuminemia严重程度和3天的负载剂量后的TEIC总水平之间的关系.
研究的目的:
- 为了研究低albuminemia严重程度和全 teicoplanin (TEIC) 最低度之间的相关性.
- 为了比较不同血清白蛋白水平的总和预测的自由TEIC最低度.
- 评估标准剂量和高负载剂量方案对不同程度的低albuminemia患者TEIC度的影响.
主要方法:
- 在2017年1月至2025年1月期间接受TEIC的患者 (≥18岁) 的回顾性研究.
- 使用多重线性回归分析来确定影响TEIC总低谷度 (C粗略) 的因素.
- 患者的血清白蛋白 (Alb) 水平被分为三个组 (<2.0 g/dL,2.02.9 g/dL,≥3.0 g/dL) 来评估低白蛋白血症的严重程度.
主要成果:
- 总TEIC C粗略显示了与年龄和估计的膜过率的负相关性,以及与体重,血清Alb和TEIC加载剂量的正相关性.
- 在标准剂量和高负载剂量方案中,在白蛋白组之间观察到中位数总TEIC C粗略的显著差异.
- 预测的自由TEIC C粗略在两个剂量方案中的白蛋白组之间没有显著差异.
结论:
- 总TEIC C随着低albuminemia严重程度的增加而大致减少.
- 预测免费的TEIC C粗略可能不会受到低albuminemia严重程度的显著影响.
- 考虑较低的目标TEIC总度可能对患有低albuminemia的患者有益.
相关概念视频
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
220
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
220
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
224
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
224
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
291
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
291
01:29Therapeutic Drug Monitoring: Affecting Factors
183
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
183
01:09Hepatic Drug Clearance: Effect of Protein Binding
505
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
505
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241